Effect of CYP2C19*2 and*17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications

American Journal of Cardiology

Volumn 111, Issue 7, 2013, Pages 985-990

  Grosdidier, Charlotte ^a,b   Quilici, Jacques ^b,c   Loosveld, Marie ^a,b,c   Camoin, Laurence ^a,b,c   Moro, Pierre Julien ^b,c   Saut, Noémie ^a,b   Gaborit, Bénédicte ^a,b   Pankert, Mathieu ^b,c   Cohen, William ^a,b,c   Lambert, Marc ^b,c   Beguin, Shirley ^d   Morange, Pierre Emmanuel ^a,b,c   Bonnet, Jean Louis ^a,b,c   Alessi, Marie Christine ^b,c   Cuisset, Thomas ^a,b,c  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c TIMONE HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; CELL ADHESION MOLECULE; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; PHOSPHOPROTEIN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BLEEDING; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PLATELET REACTIVITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ACUTE CORONARY SYNDROME; ALLELE; DRUG EFFECT; GENETICS; HEART INFARCTION; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; CELL ADHESION MOLECULES; FEMALE; GENETIC VARIATION; GENOTYPE; HEMORRHAGE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOPROTEINS; PIPERAZINES; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875225074     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.12.013     Document Type: Article

References (30)

1. M.E. Bertrand, H.J. Rupprecht, P. Urban, A.H. Gershlick Investigators FT Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
3. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, M.K. Natarajan, K. Malmberg, H. Rupprecht, F. Zhao, S. Chrolavicius, I. Copland, K.A. Fox Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
4. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, T.A. Bass, and M.A. Costa Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
5. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, N. Saut, D. Faille, M. Lambert, I. Juhan-Vague, J.L. Bonnet, and M.C. Alessi Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
6. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, J. Silvain, L. Payot, D. Brugier, G. Cayla, F. Beygui, G. Bensimon, C. Funck-Brentano, and G. Montalescot Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
7. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, O. Barthélémy, G. Cayla, F. Beygui, and G. Montalescot Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
8. C. Frere, T. Cuisset, B. Gaborit, M.C. Alessi, and J.S. Hulot The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome J Thromb Haemost 7 2009 1409 1411
9. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, J. Stegherr, T. Morath, A. Schömig, N. von Beckerath, and A. Kastrati Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
10. S.D. Wiviott, E.M. Antman, K.J. Winters, G. Weerakkody, S.A. Murphy, B.D. Behounek, R.J. Carney, C. Lazzam, R.G. McKay, C.H. McCabe, E. Braunwald JUMBO-TIMI 26 Investigators Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 111 2005 3366 3373
11. J.T. Brandt, C.D. Payne, S.D. Wiviott, G. Weerakkody, N.A. Farid, D.S. Small, J.A. Jakubowski, H. Naganuma, and K.J. Winters A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J 153 2007 66.e9 66.e16
12. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, C.M. Gibson, E.M. Antman TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
13. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, J.T. Brandt, J.R. Walker, E.M. Antman, W.L. Macias, E. Braunwald, and M.S. Sabatine Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
14. J.T. Brandt, S.L. Close, S.J. Iturria, C.D. Payne, N.A. Farid, C.S. Ernest II, D.R. Lachno, D. Salazar, and K.J. Winters Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
15. T. Cuisset, M. Loosveld, P.E. Morange, J. Quilici, P.J. Moro, N. Saut, B. Gaborit, C. Castelli, S. Beguin, C. Grosdidier, L. Fourcade, J.L. Bonnet, and M.C. Alessi CYP2C19*2 and*17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome JACC Cardiovasc Interv 5 2012 1280 1287
16. U.R. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 1999 1145 1152
17. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, R. Becker, D.L. Bhatt, M. Cattaneo, J.P. Collet, T. Cuisset, C. Gachet, G. Montalescot, L.K. Jennings, D. Kereiakes, D. Sibbing, D. Trenk, J.W. Van Werkum, F. Paganelli, M.J. Price, R. Waksman, P.A. Gurbel Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
18. R. Mehran, S.V. Rao, D.L. Bhatt, C.M. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S.D. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J.F. Sabik, D.E. Cutlip, M.W. Krucoff, E.M. Ohman, P.G. Steg, and H. White Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
19. L. Bonello, M. Pansieri, J. Mancini, R. Bonello, L. Maillard, P. Barnay, P. Rossi, O. Ait-Mokhtar, B. Jouve, F. Collet, J.P. Peyre, O. Wittenberg, A. de Labriolle, E. Camilleri, E. Cheneau, E. Cabassome, F. Dignat-George, L. Camoin-Jau, and F. Paganelli High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes J Am Coll Cardiol 58 2011 467 473
20. A.D. Michelson, A.L. Frelinger III, E. Braunwald, W.E. Downey, D.J. Angiolillo, N.P. Xenopoulos, J.A. Jakubowski, Y. Li, S.A. Murphy, J. Qin, C.H. McCabe, E.M. Antman, S.D. Wiviott TRITON-TIMI 38 Investigators Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
21. D.J. Angiolillo, J.J. Badimon, J.F. Saucedo, A.L. Frelinger, A.D. Michelson, J.A. Jakubowski, B. Zhu, C.K. Ojeh, B.A. Baker, and M.B. Effron A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial Eur Heart J 32 2011 838 846
22. D. Alexopoulos, I. Xanthopoulou, P. Davlouros, T.E. Plakomyti, A. Panagiotou, E. Mavronasiou, and G. Hahalis Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel Am Heart J 162 2011 733 739
23. G. Parodi, B. Bellandi, F. Venditti, N. Carrabba, R. Valenti, A. Migliorini, S. Grassellini, E. Ramazzotti, and D. Antoniucci Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel Am J Cardiol 109 2012 214 218
24. D. Alexopoulos, A. Galati, I. Xanthopoulou, E. Mavronasiou, G. Kassimis, K.C. Theodoropoulos, G. Makris, A. Damelou, G. Tsigkas, G. Hahalis, and P. Davlouros Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study J Am Coll Cardiol 60 2012 193 199
25. T. Cuisset, G. Cayla, C. Frere, J. Quilici, R. Poyet, B. Gaborit, L. Bali, P.E. Morange, M.C. Alessi, and J.L. Bonnet Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome: shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
26. D. Sibbing, S. Schulz, S. Braun, T. Morath, J. Stegherr, J. Mehilli, A. Schömig, N. von Beckerath, and A. Kastrati Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
27. P. Roy, L. Bonello, R. Torguson, A. de Labriolle, G. Lemesle, T.L. Slottow, D.H. Steinberg, K. Kaneshige, Z. Xue, L.F. Satler, K.M. Kent, W.O. Suddath, A.D. Pichard, J. Lindsay, and R. Waksman Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation Am J Cardiol 102 2008 1614 1617
28. S. Armero, L. Bonello, J. Berbis, L. Camoin-Jau, G. Lemesle, L. Jacquin, C. Bonello-Burignat, M. Pansieri, F. Collet, M. Ostorero, F. Dignat-George, and F. Paganelli Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes Am J Cardiol 108 2011 1710 1713
29. G. Cayla, J.S. Hulot, S.A. O'Connor, A. Pathak, S.A. Scott, Y. Gruel, J. Silvain, J.B. Vignalou, Y. Huerre, A. de la Briolle, F. Allanic, F. Beygui, O. Barthélémy, G. Montalescot, and J.P. Collet Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis JAMA 306 2011 1765 1774
30. J.P. Collet, T. Cuisset, G. Rangé, G. Cayla, S. Elhadad, C. Pouillot, P. Henry, P. Motreff, D. Carrié, Z. Boueri, L. Belle, E. Van Belle, H. Rousseau, P. Aubry, J. Monségu, P. Sabouret, S.A. O'Connor, J. Abtan, M. Kerneis, C. Saint-Etienne, O. Barthélémy, F. Beygui, J. Silvain, E. Vicaut, G. Montalescot ARCTIC Investigators Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109